A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of oral RSV604 in healthy adults experimentally infected with respiratory syncytial virus.
Latest Information Update: 17 Nov 2012
Price :
$35 *
At a glance
- Drugs RSV 604 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2011 New trial record